Cancer Therapies: A Global Strategic Business Report
San Jose, California (PRWEB) November 21, 2011
Follow us on LinkedIn – Cancer therapy represents one of the fastest growing segments of the pharmaceutical industry, driven largely by increasing incidences of cancer and significant unmet needs. The medical community’s arsenal of weapons in the battle against cancer ranges from conventional radiotherapy, chemotherapy to new breakthrough gene therapy treatment regimes. Most of the cancer therapies are developed based on monoclonal antibodies, colony stimulating factors, hormones and cytokines, gene therapy, antisense oligonucleotides, oncolytic viruses, and cancer vaccines among others. Undesirable side effects associated with chemotherapy, and lower levels of patient compliance are fingered as prime reasons for the waning popularity of chemotherapy. Nevertheless, chemotherapy is expected to get a fresh lease of life, given the imminent availability of generic versions of cytotoxic drugs, which are likely to lose their exclusivity in the upcoming years. Also, demand for chemotherapy drugs is expected to receive a boost from increasing use of these traditional therapies in combination with new cancer therapies, as a means to increase efficacy profiles.
Cancer therapies are treatments indicated for controlling growth of cancerous tumors. The choice of cancer therapy is largely dependent upon individual patient’s response towards a particular treatment. Despite the significant breakthroughs in cancer therapies over the years, which have helped improve survival rates, there still exist chances of failure resulting in disease relapse. Side effects associated with the treatment therapies still remain a major cause of concern. For instance, use of radiation therapy, surgery and chemotherapy for treating neck and head cancers could affect the head and neck arrangement and make eating, swallowing and breathing difficult. Therefore, research is underway in the development of new solutions that enhance clinical efficacy, while simultaneously reducing toxicity and undesirable side effects. Combination therapies and targeted therapies are forecast to drive cancer therapy market in the future. Currently approved combination therapies include paclitaxel, and carboplatin together with Avastin indicated for the treatment of non-small cell lung cancer, and Avastin, and Paclitaxel combo for treating metastatic breast cancer.
Monoclonal Antibodies (mAbs), which find use in immunotherapeutics and targeted therapies, play a key role in the development of various cancer treatments. These artificial antibodies are produced in laboratories and are designed specifically for a particular antigen, which means that antibodies designed for one type of cancer cannot be used for other types. Biotechnology-based cancer drugs, including Avastin, Herceptin, and Gleevec are developed based on monoclonal antibodies for treating Chronic Myeloid Leukemia and Breast Cancer. Monoclonal Antibodies such as Avastin, Nexavar, and Sutent, act as VEGF inhibitors by targeting and inhibiting the functioning of vascular endothelial growth factor, and this results in reduced blood, oxygen and nutrients supply to tumor cells, which in turn slows down the growth of cancer cells. Biotherapies represent the dominant segment in the global market for cancer therapies. The segment features several drugs that have attained blockbuster status and sales of these drugs continue to rise with each passing year. Factors such as increasing number of new and overall cancer patients worldwide, as well as the relative higher efficacy and safety profiles of biotherapies are further expected to fuel sales in this segment. Besides, some of the new drugs that were launched the recent years hold a higher price tag, promising substantial revenue growth for the market in the years to come.
As stated by the new market research report on Cancer Therapies, the US continues to remain the largest regional market worldwide. However, growth in the global cancer therapies market would be driven by developing countries. Rest of World, comprising Canada, and countries in Asia-Pacific, Latin America, the Middle East, and Africa, represents the fastest growing regional market displaying a CAGR of about 25% over the analysis period. Immunotherapy remains the largest segment for cancer therapies worldwide. Growth in the market would, however, be driven by the Targeted Therapy drugs.
Major players profiled in the report include Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline, Janssen Biotech, Inc., Merck KGaA, Novartis AG, Pfizer, Sanofi-Aventis, Takeda Pharmaceutical Company Limited, among others.
The research report titled “Cancer Therapies: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the cancer therapies markets, current market trends, key growth drivers, pipeline status of various cancer therapies, overview of clinical trial data for select drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for cancer therapies market for the years 2009 through 2017 for the following geographic markets - US, Japan, Europe, and Rest of World. The report analyzes the cancer therapies market by the following segments – Immunotherapy, Targeted Therapy, Hormone Therapy and Chemotherapy. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Cancer_Therapies_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/